Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center

被引:0
作者
Krausewitz, Philipp [1 ]
Buettner, Thomas [1 ]
von Danwitz, Marthe [1 ]
Weiten, Richard [1 ]
Cox, Alexander [1 ]
Kluemper, Niklas [1 ,2 ]
Stein, Johannes [1 ]
Luetkens, Julian [3 ]
Kristiansen, Glen [4 ]
Ritter, Manuel [1 ]
Ellinger, Jorg [1 ]
机构
[1] Univ Hosp Bonn, Dept Urol & Pediat Urol, Bonn, Germany
[2] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
[3] Univ Hosp Bonn, Dept Diagnost & Intervent Radiol, Bonn, Germany
[4] Univ Hosp Bonn, Inst Pathol, Bonn, Germany
关键词
Clinically significant prostate cancer; Prostate biopsy; mpMRI; Risk calculators;
D O I
10.1186/s12894-024-01460-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective Utilizing personalized risk assessment for clinically significant prostate cancer (csPCa) incorporating multiparametric magnetic resonance imaging (mpMRI) reduces biopsies and overdiagnosis. We validated both multi- and univariate risk models in biopsy-naive men, with and without the inclusion of mpMRI data for csPCa detection. Methods N = 565 men underwent mpMRI-targeted prostate biopsy, and the diagnostic performance of risk calculators (RCs), mpMRI alone, and clinical measures were compared using receiver operating characteristic curve (ROC) analysis and decision curve analysis (DCA). Subgroups were stratified based on mpMRI findings and quality. Results csPCa was detected in 56.3%. PI-RADS score achieved the highest area under the curve (AUC) when comparing univariate risk models (AUC 0.82, p < 0.001). Multivariate RCs showed only marginal improvement in csPCa detection compared to PI-RADS score alone, with just one of four RCs showing significant superiority. In mpMRI-negative cases, the non-MRI-based RC performed best (AUC 0.80, p = 0.016), with the potential to spare biopsies for 23%. PSA-density and multivariate RCs demonstrated comparable performance for PI-RADS 3 constellation (AUC 0.65 vs. 0.60-0.65, p > 0.5; saved biopsies 16%). In men with suspicious mpMRI, both mpMRI-based RCs and the PI-RADS score predicted csPCa excellently (AUC 0.82-0.79 vs. 0.80, p > 0.05), highlighting superior performance compared to non-MRI-based models (all p < 0.002). Quality-assured imaging consistently improved csPCa risk stratification across all subgroups. Conclusion In tertiary centers serving a high-risk population, high-quality mpMRI provides a simple yet effective way to assess the risk of csPCa. Using multivariate RCs reduces multiple biopsies, especially in mpMRI-negative and PI-RADS 3 constellation.
引用
收藏
页数:9
相关论文
共 50 条
[21]   A risk index for prostate cancer [J].
Matchariyakul, C ;
Kochakarn, W ;
Chaimuangraj, S ;
Leenanupunth, C ;
Lertsithichai, P .
INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (05) :310-315
[22]   The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used? [J].
Marianne Schmid ;
Quoc-Dien Trinh ;
Markus Graefen ;
Margit Fisch ;
Felix K. Chun ;
Jens Hansen .
World Journal of Urology, 2014, 32 :871-880
[23]   The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used? [J].
Schmid, Marianne ;
Quoc-Dien Trinh ;
Graefen, Markus ;
Fisch, Margit ;
Chun, Felix K. ;
Hansen, Jens .
WORLD JOURNAL OF UROLOGY, 2014, 32 (04) :871-880
[24]   Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment [J].
Bjurlin, Marc A. ;
Mendhiratta, Neil ;
Wysock, James S. ;
Taneja, Samir S. .
CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2016, 69 (01) :9-18
[25]   Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy [J].
Zhou, Chenchao ;
Zhang, Jun ;
Chen, Ye ;
Wang, Hao ;
Hou, Jianquan .
ONCOTARGETS AND THERAPY, 2017, 10 :3485-3491
[26]   PSCA rs1045531 Polymorphism and the Risk of Prostate Cancer in a Chinese Population Undergoing Prostate Biopsy [J].
Zhang, Xuefeng ;
Hu, Qin ;
Chen, Ye ;
Li, Miao ;
Yin, Huming ;
Zhou, Chenchao ;
Li, Gang ;
Hou, Jianquan .
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (06) :1168-1172
[27]   Prostate volume index stratified prostate cancer risk in patients elected to a first random biopsy set [J].
Porcaro, Antonio B. ;
Corsi, Paolo ;
de Luyk, Nicolo ;
Sebben, Marco ;
Tafuri, Alessandro ;
Bizzotto, Leonardo ;
Cacciamani, Giovanni ;
De Marchi, Davide ;
Processali, Tania ;
Mattevi, Daniele ;
Novella, Giovanni ;
Cerruto, Maria A. ;
Brunelli, Matteo ;
Siracusano, Salvatore ;
Artibani, Walter .
TUMORI, 2017, 103 (04) :374-379
[28]   Risk stratification of prostate cancer 2016 [J].
Reiter, Robert E. .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2016, 76 :S54-S59
[29]   Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions [J].
Phelps, Tim E. E. ;
Yilmaz, Enis C. C. ;
Harmon, Stephanie A. A. ;
Belue, Mason J. J. ;
Shih, Joanna H. H. ;
Garcia, Charisse ;
Hazen, Lindsey A. A. ;
Toubaji, Antoun ;
Merino, Maria J. J. ;
Gurram, Sandeep ;
Choyke, Peter L. L. ;
Wood, Bradford J. J. ;
Pinto, Peter A. A. ;
Turkbey, Baris .
ABDOMINAL RADIOLOGY, 2023, 48 (03) :1079-1089
[30]   Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer [J].
Pepe, Pietro ;
Pepe, Ludovica ;
Tamburo, Maria ;
Marletta, Giulia ;
Pennisi, Michele ;
Fraggetta, Filippo .
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2022, 94 (03) :274-277